RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 7, 2011 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) will present the latest data from their diabetes portfolio at the 47th ...
Ingelheim, Germany and Indianapolis, US, 10 June, 2014 – More than 40 presentations including posters, abstracts and oral presentations will demonstrate the breadth and depth of the Boehringer ...
A total of eight clinical abstracts for the investigational agent empagliflozin will be presented. Empagliflozin is a sodium glucose co-transporter 2 (SGLT2) inhibitor being investigated for the ...
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, announced data presented this week on real-world use of the t:slim ...
INDIANAPOLIS, May 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), ...
The American Diabetes Association’s 74th Scientific Sessions, held in San Francisco, addressed various emerging areas of study in the treatment of type 1 and type 2 diabetes. Presentations addressed ...
Tweet this “People living with diabetes are benefiting from our Control-IQ technology across diverse populations and therapeutic backgrounds, which supports our mission to improve the lives of people ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback